Strides Pharma Science Limited has announced a transition in its statutory auditors. Upon the conclusion of the 36th Annual General Meeting in 2027, the current auditors, B S R & Co. LLP, will complete their second five-year term. The Board of Directors has recommended the appointment of Deloitte Haskins & Sells LLP for a subsequent five-year term, covering the period from 2027 to 2032, subject to approval by the company’s shareholders.
Planned Auditor Rotation
Following the completion of its second five-year tenure, the existing statutory auditor, M/s. B S R & Co. LLP, will step down at the conclusion of the 36th Annual General Meeting (AGM) scheduled for 2027. This move aligns with standard corporate governance practices regarding the rotation of audit firms.
New Appointment Details
The Board of Directors, following the recommendation of the Audit Committee, has proposed the appointment of M/s. Deloitte Haskins & Sells LLP as the new statutory auditors. This appointment is slated for a duration of five consecutive years. The firm is expected to serve from the conclusion of the 36th AGM in 2027 until the conclusion of the 41st AGM in 2032.
Next Steps for Shareholders
The formal appointment of Deloitte Haskins & Sells LLP is subject to final approval from the shareholders of Strides Pharma Science Limited. This approval process will be conducted during the 36th AGM to be held in 2027, ensuring transparent transition and corporate compliance throughout the appointment process.
Source: BSE
